Semaglutide vs Tirzepatide vs Retatrutide.

The GLP-1 showdown: comparing the three most important incretin-based weight loss compounds by mechanism, efficacy, safety, and availability.

Weight LossGLP-1ComparisonMetabolic
The incretin revolution has produced three landmark compounds, each building on the last. Semaglutide proved that GLP-1 receptor agonism could produce clinically meaningful weight loss. Tirzepatide demonstrated that adding GIP agonism amplified the effect. Now retatrutide suggests that a third receptor, glucagon, may push efficacy even further. This three-way comparison examines the mechanisms, clinical data, safety profiles, and practical availability of the compounds reshaping metabolic medicine.
◆ ◆ ◆

Head-to-Head Comparison.

Brand NamesOzempic / Wegovy / RybelsusMounjaro / ZepboundLY3437943 (no brand yet)
DeveloperNovo NordiskEli LillyEli Lilly
Receptor TargetsGLP-1 onlyGIP + GLP-1 (dual)GIP + GLP-1 + Glucagon (triple)
Mechanism TypeSingle agonistDual agonistTriple agonist
Max Clinical Dose2.4mg weekly (Wegovy)15mg weekly (Zepbound)12mg weekly (Phase 2)
Mean Weight Loss~14.9% (STEP 1, 68 wk)~22.5% (SURMOUNT-1, 72 wk)~24.2% (Phase 2, 48 wk)
Key TrialSTEP programSURMOUNT programPhase 2 (NEJM 2023)
FDA StatusApproved (T2DM + Obesity)Approved (T2DM + Obesity)Investigational (Phase 3)
Half-Life~7 days~5 days~6 days
DosingOnce weekly SC injectionOnce weekly SC injectionOnce weekly SC injection
GI Side EffectsNausea 44%, diarrhea 30%Nausea 31%, diarrhea 23%Nausea 16-45% (dose-dep)
Oral OptionYes (Rybelsus)NoNo
CV Outcomes DataYes (SELECT trial: 20% MACE reduction)Pending (SURPASS-CVOT)No
Unique AdvantageMost clinical data; oral option; CV outcomes provenHighest approved weight loss; dual mechanismHighest total weight loss; liver fat clearance
◆ ◆ ◆

The Mechanism Ladder.

These three compounds represent a progression in receptor pharmacology. Semaglutide activates only GLP-1 receptors, driving appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. Tirzepatide adds GIP receptor agonism, which enhances insulin sensitivity, may improve lipid handling in adipose tissue, and contributes additional central appetite regulation. Retatrutide adds glucagon receptor agonism on top, introducing a mechanism that increases energy expenditure through hepatic lipid oxidation and thermogenesis. Each additional receptor target adds metabolic complexity, and the clinical data suggests each addition produces incrementally greater weight loss.

Efficacy Data.

The weight loss data forms a clear progression: semaglutide at 14.9% (68 weeks), tirzepatide at 22.5% (72 weeks), and retatrutide at 24.2% (48 weeks, Phase 2). However, direct comparison requires caution. The trials used different patient populations, durations, and dose escalation protocols. Retatrutide achieved its numbers in 48 weeks versus 68-72 for the others, suggesting the trajectory may continue upward with longer treatment. Approximately one-third of semaglutide patients achieved 20%+ weight loss, while over half of tirzepatide and retatrutide patients at highest doses exceeded this threshold. Retatrutide also showed near-complete liver fat resolution in participants with MASLD.

Safety Profiles.

GI side effects are the class hallmark. Nausea, diarrhea, vomiting, and constipation are common with all three, generally worst during dose escalation and improving over time. Semaglutide has the most extensive long-term safety data from years of post-marketing surveillance. Tirzepatide has growing real-world data. Retatrutide has only Phase 2 data, so its safety profile is the least characterized. All carry the thyroid C-cell boxed warning based on rodent studies. The glucagon component in retatrutide raises theoretical concerns about glycemic effects, though hyperglycemia was not a significant finding in trials. Lean mass loss is a documented concern with all three and requires mitigation through resistance training and protein intake.

Availability & Access.

Semaglutide is the most accessible: FDA-approved under multiple brand names, available in both injectable and oral formulations, and increasingly available through telehealth platforms. Tirzepatide is FDA-approved but has experienced supply constraints since launch. Retatrutide is not available through standard prescription channels, as it remains in Phase 3 clinical trials. Research-grade versions of all three are available from peptide and GLP-1 research suppliers, though quality verification is especially important for investigational compounds like retatrutide.

◆ The Verdict

Best overall evidence base: Semaglutide. Years of post-marketing data, proven cardiovascular outcomes (SELECT trial), oral option available, and the broadest clinical experience.

Best weight loss per approved compound: Tirzepatide. The dual GIP/GLP-1 mechanism produces greater weight loss than semaglutide with a similar safety profile. The clear choice when maximum efficacy from an FDA-approved option is the priority.

Highest ceiling (investigational): Retatrutide. The triple-agonist mechanism has shown the greatest weight loss data to date, with remarkable liver fat clearance. However, it is investigational, with limited safety data and no regulatory approval. Phase 3 results will determine whether it lives up to Phase 2 promise.
◆ ◆ ◆

Source These Compounds.

Verified research peptide suppliers

BioPure Peptides

Premium research peptides with third-party COAs. Use code POWER at checkout.

Code: POWER
Shop Now →

Apollo Peptide Sciences

Research-grade peptides with Refersion-tracked affiliate program.

Shop Now →

GLP-1 Research Lab

Specialist GLP-1 receptor agonist supplier for research use.

Shop Now →

Offline Peptides

75+ peptides, HPLC-verified, third-party COAs. Free shipping $250+.

Shop Now →
◆ ◆ ◆

Frequently Asked Questions.

Research Disclaimer: Content on PowerPeptides.co is for informational and research purposes only. It is not medical advice. Peptides discussed are research compounds unless explicitly noted as FDA-approved. Always consult a licensed healthcare provider before beginning any peptide protocol. Full Disclaimer | Affiliate Disclosure